BS_0RF0EZTV
Neurofibroma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Neurofibroma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Neurofibroma
- overall_survival_months
- 45.367936925098554
- age_years
- 11.34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.648
- TNFA_SIGNALING_VIA_NFKB+0.644
- INTERFERON_GAMMA_RESPONSE+0.643
- INFLAMMATORY_RESPONSE+0.587
- ALLOGRAFT_REJECTION+0.585
- IL6_JAK_STAT3_SIGNALING+0.569
- IL2_STAT5_SIGNALING+0.483
- COMPLEMENT+0.468
- ANGIOGENESIS+0.467
- APOPTOSIS+0.464
Top 10 suppressed
- E2F_TARGETS-0.490
- G2M_CHECKPOINT-0.408
- OXIDATIVE_PHOSPHORYLATION-0.385
- MYC_TARGETS_V2-0.341
- SPERMATOGENESIS-0.340
- MTORC1_SIGNALING-0.318
- PANCREAS_BETA_CELLS-0.271
- MYC_TARGETS_V1-0.218
- GLYCOLYSIS-0.201
- PEROXISOME-0.172
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NDRDM2A9 | Neurofibroma | — | 0.964 |
| 2 | BS_TAHV8N04 | Neurofibroma | — | 0.943 |
| 3 | BS_69V8P8A0 | Neurofibroma | — | 0.937 |
| 4 | BS_FQX1PRAJ | Neurofibroma | — | 0.935 |
| 5 | BS_GDHH6T5A | Neurofibroma | — | 0.934 |
| 6 | BS_2W3NC4K1 | Neurofibroma | — | 0.931 |
| 7 | BS_TQ5QHR17 | Neurofibroma | — | 0.930 |
| 8 | BS_893A91ZM | Neurofibroma | — | 0.930 |
| 9 | BS_RQSKD7PN | MPNST | — | 0.928 |
| 10 | BS_49VCQD19 | Neurofibroma | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.648 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.644 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.643 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.587 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.585 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.569 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.483 | Idelalisib | — uncovered |
| COMPLEMENT | 0.468 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.467 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.464 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.464 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.445 | Inavolisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.379 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.365 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.353 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.291 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.288 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.263 | Inavolisib | — uncovered |